Literature DB >> 2545842

Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2.

M C Kuppner1, M F Hamou, Y Sawamura, S Bodmer, N de Tribolet.   

Abstract

Human glioblastoma cells secrete an inhibitory factor termed "glioblastoma-derived T-cell suppressor factor" (G-TsF). A member of the transforming growth factor beta (TGF beta) family, G-TsF is identical to TGF beta 2. The present study investigated the effect of G-TsF/TGF beta 2 on the proliferative and cytotoxic properties of tumor-infiltrating lymphocytes (TIL's) isolated from malignant gliomas after expansion in vitro with interleukin-2 (IL-2). The results demonstrate that the IL-2 (5 to 20 U/ml)-dependent proliferative response of glioma-derived TIL's was inhibited 70% to 85% by G-TsF/TGF beta 2 and that the inhibitory effect could be reduced by using increasing concentrations of IL-2 (100 to 200 U/ml). Tumor necrosis factor alpha (TNF alpha) enhanced the IL-2-dependent proliferation of TIL's cultured in low concentrations of IL-2 (10 U/ml); however, neither TNF alpha nor interferon gamma was able to reduce the inhibitory effect of TGF beta 2 on TIL proliferation. In addition, TGF beta 2 suppressed 60% to 100% the cytotoxic response of glioma-derived TIL's against several tumor targets, including autologous glioma cells, and the suppressive effect was shown to be reduced by increasing concentrations of IL-2.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545842     DOI: 10.3171/jns.1989.71.2.0211

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  41 in total

Review 1.  Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

Authors:  Steven De Vleeschouwer; Stefaan W Van Gool; Frank Van Calenbergh
Journal:  Childs Nerv Syst       Date:  2004-09-28       Impact factor: 1.475

2.  TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.

Authors:  Yang Liu; Qing Wang; B K Kleinschmidt-DeMasters; Alex Franzusoff; Ka-yun Ng; Kevin O Lillehei
Journal:  J Neurooncol       Date:  2006-08-29       Impact factor: 4.130

Review 3.  Molecular analysis of pediatric brain tumors.

Authors:  Jaclyn A Biegel; Ian F Pollack
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

4.  Augmentation of natural killer cell activity in mice by oral administration of transforming growth factor-beta.

Authors:  S Ishizaka; M Kimoto; S Kanda; S Saito
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

Review 5.  Overview of cellular immunotherapy for patients with glioblastoma.

Authors:  Elodie Vauleon; Tony Avril; Brigitte Collet; Jean Mosser; Véronique Quillien
Journal:  Clin Dev Immunol       Date:  2010-10-04

6.  Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors.

Authors:  L H Elliott; W H Brooks; T L Roszman
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

7.  Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.

Authors:  L M Weiskirch; Y Bar-Dagan; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

8.  Cytokine gene expression on glioma cell lines and specimens.

Authors:  R Yamanaka; R Tanaka; T Saitoh; S Okoshi
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 9.  Passive immunotherapeutic strategies for the treatment of malignant gliomas.

Authors:  Daniel T Nagasawa; Christina Fong; Andrew Yew; Marko Spasic; Heather M Garcia; Carol A Kruse; Isaac Yang
Journal:  Neurosurg Clin N Am       Date:  2012-07       Impact factor: 2.509

10.  TM-1 cells from an established human malignant glioma cell line produce PDGF, TGF-alpha, and TGF-beta which cooperatively play a stimulatory role for an autocrine growth promotion.

Authors:  M Kurimoto; S Endo; K Arai; Y Horie; K Nogami; A Takaku
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.